Sanofi reaps first fruit of Ablynx buyout with a European OK for its lead rare disease drug

Submitted by admin on September 4, 2018 - 5:01pm

Source:

Endpoints

News Tags:

Ablynx

Sanofi

Europe

caplacizumab

M&A

aTTP

Headline:

Sanofi reaps first fruit of Ablynx buyout with a European OK for its lead rare disease drug

snippet:

Just weeks after closing its $4.8 billion acquisition of Ablynx, Sanofi has bagged a European approval for its lead drug, caplacizumab, which treats an ultra-rare blood clotting disease.

Search form

You are here

Sanofi reaps first fruit of Ablynx buyout with a European OK for its lead rare disease drug

Sanofi reaps first fruit of Ablynx buyout with a European OK for its lead rare disease drug